Galidesivir is primarily investigated for its antiviral properties, particularly in treating RNA virus infections. It has shown potential in combating viruses such as Ebola, Zika, and Marburg by inhibiting viral RNA polymerase, thus preventing viral replication. Recent studies also explore its efficacy against SARS-CoV-2, the virus responsible for COVID-19, due to its broad-spectrum antiviral activity. Its mechanism of action makes it a promising candidate for addressing emerging viral threats and outbreaks. Research continues to evaluate its safety, effectiveness, and potential use in clinical settings.